Despite many recent advances in immunodermatological treatments with breakthrough therapies, a large proportion of patients unfortunately develop systemic side-effects due to their current treatment and are in need of new localized treatment options. We at CAGE Bio are committed to addressing this unmet medical need.
Our commitment includes developing novel products for dermatology, inflammation, and immunology and conducting clinical trials with our investigational products to demonstrate their safety and efficacy. Data from these clinical trials ultimately could support regulatory approval, allowing these products to become available for the benefit of many patients.
Patients who choose to participate in clinical trials play a critical role in the development of these and other new products. If you are interested in gaining access to our investigational products, we encourage you to speak with your physician about the possibility of enrolling in a clinical trial.
This section provides information on CAGE Bio clinical trials that are currently active:
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis